Olipass Corp
244460
Company Profile
Business description
Olipass Corp is a South Korea based biotechnology company engaged in developing its platform OliPass PNA which focuses on introducing cationic lipid moiety onto nucleobase. Its pipeline products include SC Injection, Hyper Cholesterolemia, Chemo/Radio-sensitizer, and Type II Diabetes among others.
Contact
16-4, 16 Beon-gil, Dongbaek Jungang-ro
Ace Dongbaek Tower 20th Floor
Giheung-gu
Yongin17015
KORT: +82 3180608200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
27
Stocks News & Analysis
stocks
Wide moat share expects luck to turn
A tough year for jackpots however earnings are expected to normalise.
stocks
ASX share’s growth story intact despite supply constraints
Short term supply challenges but Chinese growth story remains intact.
stocks
ASX healthcare giant rallies despite a fall in profits
Easing investor concerns and signalling a return to growth.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,269.70 | 13.70 | -0.15% |
| CAC 40 | 8,475.66 | 22.57 | 0.27% |
| DAX 40 | 26,090.51 | 107.47 | 0.41% |
| Dow JONES (US) | 52,759.21 | 703.84 | -1.32% |
| FTSE 100 | 10,779.35 | 31.19 | 0.29% |
| HKSE | 26,009.46 | 310.97 | 1.21% |
| NASDAQ | 26,067.17 | 263.92 | -1.00% |
| Nikkei 225 | 66,016.36 | 200.43 | -0.30% |
| NZX 50 Index | 13,972.66 | 52.84 | 0.38% |
| S&P 500 | 7,641.16 | 0.00 | 0.00% |
| S&P/ASX 200 | 9,058.90 | 6.90 | -0.08% |
| SSE Composite Index | 3,905.20 | 1.48 | 0.04% |